IOVA Nasdaq

Iovance Biotherapeutics, Inc.

IOVA 4 | $11.71 -1.27% -1.45% 2.9M

(0.0% 1d) (-16.7% 1m) (114.1% 1y) (0.0% 2d) (-1.3% 3d) (3.5% 7d) (-24.72% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 3,270,685,474
http://www.iovance.com
Sec Filling | Patents | 148 employees

(US) Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

cancer immunotherapy t-cell msa ceiling

add to watch list Paper trade email alert is off

Press-releases

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-04-19 (Crawled : 21:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| Email alert Add to watchlist
nasdaq grants

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-03-22 (Crawled : 22:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| Email alert Add to watchlist
nasdaq grants

Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| -30.26% | O: 7.77% H: 0.8% C: -6.27%
lun-202 fda lung lifted cancer cell trial

Iovance Biotherapeutics to Present at Upcoming Conferences
Published: 2024-03-01 (Crawled : 22:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| Email alert Add to watchlist

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| -32.82% | O: -3.44% H: 3.45% C: -5.47%
year results

How Upcoming KRAS Inhibitors are Expected to Shape the Future Oncology Market Landscape?
Published: 2024-02-26 (Crawled : 17:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M

Health Technology

| -7.93% | O: 0.52% H: 0.0% C: 0.0%
RVMD | $35.59 -1.85% -1.97% 1.3M

Health Technology

| 19.67% | O: 0.4% H: 2.75% C: 1.74%
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| -25.75% | O: 0.19% H: 9.37% C: 5.06%
expected market

Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| -25.75% | O: 3.8% H: 3.4% C: -2.63%
conference financial results

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| 27.98% | O: 27.32% H: 15.11% C: 3.26%
million offering

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| 27.98% | O: 27.32% H: 15.11% C: 3.26%
fda melanoma approval advanced

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-02-16 (Crawled : 23:00) - globenewswire.com
IOVA 4 | $11.71 -1.27% -1.45% 2.9M

Health Technology

| Email alert Add to watchlist
nasdaq grants

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001104659-24-048429	4	2024-04-17	2024-04-15	Sell	M	20834	62504
0001104659-24-048429	4	2024-04-17	2024-04-15	Sell	F	8851	141334
0001104659-24-048429	4	2024-04-17	2024-04-15	Buy	M	20834	150185
0001104659-24-048428	4	2024-04-17	2024-04-15	Sell	M	2812	8439
0001104659-24-048428	4	2024-04-17	2024-04-15	Sell	F	1427	42562
0001104659-24-048428	4	2024-04-17	2024-04-15	Buy	M	2812	43989
0001104659-24-048427	4	2024-04-17	2024-04-15	Sell	M	2812	8439
0001104659-24-048427	4	2024-04-17	2024-04-15	Sell	F	1427	38026
0001104659-24-048427	4	2024-04-17	2024-04-15	Buy	M	2812	39453
0001104659-24-031115	4	2024-03-05	2024-03-01	Buy	A	25000	25000
0001104659-24-031114	4	2024-03-05	2024-03-01	Buy	A	100000	100000